TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19417734
Drug: Standard-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose tirofiban (0.4 microg x kg(‐1) x min(‐1) bolus for 30 min, followed by 0.10 microg x kg(‐1) x min(‐1) infusion for 36-48 h)
Study: 19417734
Drug: Low-dose tirofiban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tirofiban (0.4 microg x kg(‐1) x min(‐1) bolus for 30 min, followed by 0.075 microg x kg(‐1) x min(‐1) infusion for 36-48 h)
Study: 22490713
Drug: Standard-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose tirofiban
Study: 19417734
Drug: Low-dose tirofiban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tirofiban
Study: 17448840
Drug: Standardized surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized surgical and analgesic protocols
Study: 11061578
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (200 mL double-strength three times a day for 3 days)
Study: 9311179
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (100 microgram tablets)
Study: 9311179
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin E2 gel (1.5 mg)
Study: 8393389
Drug: Lisinopril therapy
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril therapy in subjects with high norepinephrine levels
Study: 8393389
Drug: Lisinopril therapy
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril therapy in subjects with low norepinephrine levels
Study: 2878272
Drug: Intrathecally administered
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecally administered natural human fibroblast interferon (IFN-B)
Study: 29346838
Drug: BMS-962212 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-962212 (20 mg h-1)
Study: 14996065
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% ointment under occlusion for 48 h
Study: 14996065
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1% ointment under occlusion for 48 h
Study: 10626714
Drug: Ropivacaine 0.2%/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2%/2 microg x ml(‐1) fentanyl
Study: 10626714
Drug: Bupivacaine 0.125%/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125%/2 microg x ml(‐1) fentanyl
Study: 9127122
Drug: Indobufen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (200 mg/day)
Study: 8233639
Drug: Pefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (400 mg q 12 h)
Study: 8233639
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg q 12 h)
Study: 8233639
Drug: Pefloxacin and
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin and Ofloxacin with Ketoprofen (100 mg daily)
Study: 27044069
Drug: Participants who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who endorsed false beliefs about biological differences rated the black patient's pain as lower and made less accurate treatment recommendations.
Study: 27044069
Drug: Participants who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who did not endorse false beliefs about biological differences rated the black patient's pain as higher.
Study: 25558905
Drug: Multi-vitamin-mineral preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-vitamin-mineral preparation supplemented with 300 mg guarana (Ac)
Study: 25558905
Drug: Caffeine supplement
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplement (C)
Study: 25558905
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement (Pl)
Study: 19560638
Drug: ST/G autografts
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST/G autografts
Study: 18575221
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel for 12 weeks
Study: 18575221
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel for 6 weeks followed by tazarotene 0.1% cream for 6 weeks (switch therapy)
Study: 12477620
Drug: ACE-I (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-I (5 mg of enalapril)
Study: 8963482
Drug: Convulsofin (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convulsofin (test) tablets (2 tablets each containing 300 mg calcium valproate, 263.4 mg valproic acid)
Study: 8963482
Drug: Convulsofin (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convulsofin (test) tablets
Study: 8963482
Drug: ref.A (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ref.A (2 dragees each of 300 mg calcium valproate)
Study: 8963482
Drug: ref.B (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ref.B (600 mg sodium valproate in liquid form)
Study: 1785001
Drug: Intravesical chemo-
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemo- and immunotherapy
Study: 1785001
Drug: Adjuvant prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant prophylactic treatments
Study: 1785001
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of T1G3 cancer
Study: 26469986
Drug: Rapid combination
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid combination antiretroviral therapy (ART) initiated by pregnant women
Study: 21864886
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality integrative medicine (CM‐IM) including hypnosis, therapeutic massage, and healing touch with each cycle of chemotherapy
Study: 21864886
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality integrative medicine (CM‐IM)
Study: 21864886
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without CM‐IM
Study: 17915642
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (loxoprofen 60 mg tablets)
Study: 17915642
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (loxoprofen 60 mg tablets)
Study: 15548972
Drug: Everolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (3 mg/day) + Reduced-Dose Neoral (RDN)
Study: 15548972
Drug: Everolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (3 mg/day) + Full-Dose Neoral (FDN)
Study: 11672943
Drug: Flunitrazepam 0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.16 mg (slow onset)
Study: 11672943
Drug: Flunitrazepam 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.8 mg (fast onset)
Study: 11672943
Drug: Flunitrazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.25 mg (slow onset)
Study: 11672943
Drug: Flunitrazepam 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1.25 mg (fast onset)
Study: 11672943
Drug: Flunitrazepam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.4 mg (slow onset)
Study: 11672943
Drug: Flunitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2 mg (fast onset)
Study: 9141914
Drug: Dopexamine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine (all doses)
Study: 7944696
Drug: Heparin-coated bypass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated bypass circuits with an uncoated cardiotomy reservoir
Study: 7944696
Drug: Heparin-coated bypass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated bypass circuits
Study: 30479531
Drug: Concurrent Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Training (CT) - high-intensity intermittent training plus strength training, performed twice weekly for 12 weeks.
Study: 30479531
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training (ST) - strength training sessions only, performed twice weekly for 12 weeks.
Study: 28578652
Drug: CROSS protocol
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CROSS protocol (Carboplatin and Paclitaxel with concurrent radiotherapy, 41.4Gy/23Fr, over 5 weeks)
Study: 28578652
Drug: Standard perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard perioperative chemotherapy regimen (not explicitly detailed in the abstract)
Study: 12698181
Drug: irinotecan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 200 mg x m(‐2) on day 1 plus raltitrexed 3 mg x m(‐2) on day 2 (arm B)
Study: 12698181
Drug: raltitrexed 3
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: raltitrexed 3 mg x m(‐2) on day 1 (arm A)
Study: 10392322
Drug: Sibrafiban (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban (oral administration, once or twice daily for up to 28 days)
Study: 10392322
Drug: Sibrafiban (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban (once-daily dosing)
Study: 10392322
Drug: Sibrafiban (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban (twice-daily dosing)
Study: 10392322
Drug: Sibrafiban (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban (oral administration)
Study: 8694022
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g ethyl ester daily)
Study: 8694022
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (6 g ethyl ester daily)
Study: 8694022
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (6 g ethyl ester daily)
Study: 27746565
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of 10mg ephedrine
Study: 27746565
Drug: Crystalloid preloading
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid preloading with ringer lactate 15 mL.kg‐1
Study: 18179661
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg/day for 2 years
Study: 15731987
Drug: No exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exposure to known teratogenic drugs (control group)
Study: 10944479
Drug: Lycopene (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (15 mg daily) for 26 days
Study: 10944479
Drug: Lutein (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (15 mg daily) for 26 days
Study: 26231819
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) delivered via videoconference (VTC)
Study: 26231819
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) delivered in person (IP)
Study: 25264948
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin (0.05 U/kg per hour)
Study: 25264948
Drug: Standard-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose insulin (0.1 U/kg per hour)
Study: 1355791
Drug: Ronactolol 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ronactolol 30 mg
Study: 1355791
Drug: Ronactolol 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ronactolol 60 mg
Study: 1355791
Drug: Ronactolol 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ronactolol 120 mg
Study: 3899672
Drug: Prazosin 4
Normalized name: prazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 4 mg/day for 6 weeks
Study: 3899672
Drug: Alphamethyldopa 250-750
Normalized name: Alphamethyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alphamethyldopa 250-750 mg/day for 6 weeks
Study: 25225424
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 to 4), granisetron (2 mg orally on days 1 to 4), and dexamethasone (4 mg orally on day 1 and 2 mg orally on days 2 to 3)
Study: 25225424
Drug: Placebo, granisetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, granisetron (2 mg orally on days 1 to 4), and dexamethasone (8 mg orally on day 1 and 4 mg orally on days 2 to 3)
Study: 22287757
Drug: Modified intermediate-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified intermediate-dose cytarabine (mIDAC; Ara-C at a dose of 1.0 g/m(2) every 12 hours for 5 days)
Study: 22287757
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HDAC; Ara-C at a dose of 2.0 g/m(2) every 12 hours for 5 days)
Study: 22287757
Drug: Modified intermediate-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified intermediate-dose cytarabine (mIDAC)
Study: 17660839
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or autologous transplantation
Study: 15468717
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (angiotensin‐converting enzyme inhibitors, nitrates, diuretics, beta‐adrenoblockers; 27.6% received digoxin, disaggregatory agents)
Study: 9233865
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g once daily for 14 days)
Study: 9233865
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily for 21 days)
Study: 3606073
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 g immediately before vancomycin infusion, followed by 15 g at 2, 4, 6, and 8 hours)
Study: 27778191
Drug: Control (statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (statin therapy only)
Study: 19735400
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at 4 microg x kg(‐1) x min(‐1)
Study: 19735400
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at 6 microg x kg(‐1) x min(‐1)
Study: 15801953
Drug: Good response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Good response group (GRG) with <25% blasts in bone marrow within the first 2 weeks of treatment
Study: 15801953
Drug: Daunorubicin included
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin included in induction therapy
Study: 10235017
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for asymptomatic carotid artery disease with 60% or greater linear stenosis
Study: 10235017
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for symptomatic carotid artery disease with 50% or greater linear stenosis
Study: 786667
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg mephenoxalone
Study: 786667
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg paracetamol
Study: 786667
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 400 mg mephenoxalone and 900 mg paracetamol
Study: 25530068
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) plus oral morphine
Study: 25530068
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) plus oral morphine
Study: 25781235
Drug: nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide (120 mg three times a day)
Study: 25781235
Drug: acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: acarbose (50 mg three times a day)
Study: 23254437
Drug: Quinine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine plus primaquine (30 mg/day for 14 days)
Study: 23254437
Drug: Dihydroartemisinin-piperaquine plus
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine plus primaquine (30 mg/day for 14 days)
Study: 23254437
Drug: Artesunate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (200 mg dose followed by 100 mg/day for 6 days)
Study: 16458259
Drug: Testosterone (sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (sublingual administration, single dose)
Study: 15123479
Drug: School-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based care group (daily inhaled corticosteroids provided through the school)
Study: 12141848
Drug: Lecture-style educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecture-style educational program (L)
Study: 12141848
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (I and L)
Study: 9450159
Drug: Pivagabine 1800
Normalized name: pivagabine
DrugBank: Pivagabine (DB12951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivagabine 1800 mg/d for four weeks
Study: 7949496
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus famotidine (50 mg/24 h, 25th‐75th percentiles = 40‐55 mg)
Study: 7949496
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion famotidine (42 mg/24 h, 25th‐75th percentiles = 42‐52 mg)
Study: 31836930
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg at Weeks 0, 2, and 6 (induction phase)
Study: 31836930
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg at Week 14 and every 8 weeks until Week 54 (maintenance phase)
Study: 28510773
Drug: Video game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video game play plus occlusion therapy (1 hour of video game play per day for the first month plus 6 hours of occlusion therapy per day)
Study: 28510773
Drug: Occlusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusion therapy alone (6 hours per day)
Study: 26077603
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (6 weeks)
Study: 26077603
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (6 weeks)
Study: 23700731
Drug: Low-dose daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose daily de-escalatory administration of tadalafil for 2 months
Study: 23700731
Drug: On-demand medication
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand medication of tadalafil for 2 months
Study: 20416893
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg orally, 3 times daily for 7 days preoperatively
Study: 20416893
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving oral placebo
Study: 11776507
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg estradiol vaginal tablet
Study: 11776507
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g conjugated estrogen cream
Study: 8090608
Drug: Beta 2-agonist
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2-agonist (terbutaline, 500 micrograms via nebuhaler)
Study: 8090608
Drug: Beta 2-agonist
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2-agonist (terbutaline)
Study: 2899772
Drug: 1‐hour intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐hour intravenous infusion of 1.5 MU of streptokinase
Study: 2899772
Drug: 160 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/day enteric‐coated aspirin for one month
Study: 2899772
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and aspirin
Study: 23358966
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing of EC‐Asnase (ID)
Study: 23358966
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing of EC‐Asnase (FD)
Study: 15871635
Drug: Valganciclovir (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (900 mg once daily)
Study: 10994883
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion (CPM) for 5 consecutive hours per day plus physical therapy
Study: 8793703
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists or angiotensin converting enzyme inhibitors (n = 266)
Study: 8793703
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration (n = 116)
Study: 1465059
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.7 +/- 0.1 g/kg/day)
Study: 1465059
Drug: Vegetarian soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetarian soy diet (0.71 +/- 0.36 g/kg ideal body weight/day)